KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non-Current Liabilities: 2018-2024

Historic Other Non-Current Liabilities for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Dec 2024 value amounting to $11.1 million.

  • Aurinia Pharmaceuticals' Other Non-Current Liabilities rose 1.80% to $11.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.1 million, marking a year-over-year increase of 1.80%. This contributed to the annual value of $11.1 million for FY2024, which is 1.80% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $11.1 million for Q4 2024, which was up 2.43% from $10.8 million recorded in Q3 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Other Non-Current Liabilities peaked at $17.9 million during Q1 2021, and registered a low of $3.4 million during Q2 2020.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $11.7 million (2022), whereas its average is $12.4 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 58,100.00% in 2020, then tumbled by 46.63% in 2023.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Other Non-Current Liabilities stood at $16.3 million in 2020, then declined by 1.84% to $16.0 million in 2021, then dropped by 23.75% to $12.2 million in 2022, then declined by 10.57% to $10.9 million in 2023, then rose by 1.80% to $11.1 million in 2024.
  • Its Other Non-Current Liabilities was $11.1 million in Q4 2024, compared to $10.8 million in Q3 2024 and $10.9 million in Q2 2024.